1.
Pinsky MR: Sepsis: A pro- and anti-inflammatory disequilibrium syndrome. Contrib Nephrol. Basel, Karger, 2001, vol 132, pp 354–366.
2.
Adrie C, Pinsky MR: The inflammatory balance in human sepsis. Intens Care Med 2000;26:364–375.
3.
Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;15:771–778.
4.
Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Duont E: Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993;103:565–575.
5.
Adib-Conquy M, Adrie C, Moine P, Ashnoune K, Fitting C, Pinsky MR, Dhainaut JF, Cavaillon JM: NF-kB expression in mononuclear cells of septic patients resembles that observed in LPS tolerance. Am J Respir Crit Care Med 2000;162:1877–1883.
6.
van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Froelich M: Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998;351:950–953.
7.
Klosterhalfen B, Horstmann-Jungemann K, Vogel P, Dufhues G, Simon B, Kalff G, Kirkpatrick CJ, Mittermayer C, Heinrich PC: Hemodynamic variables and plasma levels of PGI2, TXA2 and IL-6 in a porcine model of recurrent endotoxemia. Circ Shock 1991;35:237–244.
8.
Abraham E, Matthay M, Dinarello CA, Vincent JL, Cohen J, Opal SM, Glauser M, Parsons P, Fisher CJ, Repine JE: Concensus Conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation. Crit Care Med 2000;28:232–235.
9.
Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A: p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicenter trial. Ro 45-2081 study group. JAMA 1997;277:1531–1538.
10.
Fisher CJ, Agosti JM, Opal SM: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996;334:1697–1702.
11.
Echtenacher B, Falk W, Mannel D, Krammer PH: Requirement of endogenous tumour necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990;145:3762–3766.
12.
van der Meer JWM: The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection. Biotherapy 1988;1:19–25.
13.
Ronco C, Ricci Z, Bellomo R: Importance of increased ultrafiltration volume and impact on mortality: Sepsis and cytokine story and the role of continuous veno-venous hemofiltration. Curr Opin Nephrol Hypertens 2001;10:755–761.
14.
De Vriese AS, Vanholder RC, Pascual M, Lameire NH, Colardyn FA: Can inflammatory cytokines be removed efficiently by continous renal replacement therapies? Intens Care Med 1999;25:903–910.
15.
Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D: Hemofiltration in human sepsis: Evidence for elimination of immunomodulatory substances. Kidney Int 1995;48:1563–1570.
16.
Gasche Y, Pascual M, Suter PM, Favre H, Chevrolet JC, Schifferli JA: Complement depletion during haemofiltration with polyacylonitrile membranes. Nephrol Dial Transplant 1996;11:117–119.
17.
Kellum JA, Johnson JP, Kramer D, Palevsky P, Brady JJ, Pinsky MR: Diffuse vs. convective therapy: Effects on mediators of inflammation in patients with severe systemic inflammatory response syndrome. Crit Care Med 1998;26:1995–2000.
18.
Goldfarb J, Golper TA: Proinflammatory cytokines and hemofiltration membranes. Am Soc Nephrol 1994;5:228–232.
19.
Braun N, Giolai M, Rosenfeld S, Banzhaff W, Fretschner R, Weinstock C, Erley C, Mueller GA, Warth H, Northoff H, Risler T: Clearance of interleukin-6 during continuous veno-venous hemofiltration in patients with septic shock: A prospective, controlled clinical study (abstract). J Am Soc Nephrol 1993;4:336.
20.
Mariano F, Tetta C, Guida GE, Triolo G, Camussi G: Hemofiltration reduces the priming activity on neutrophil chemiluminescence in septic patients. Kidney Int 2001;60:1598–1605.
21.
Ronco C, Tetta C, Lupi A, Galloni E, Bettini MC, Sereni L, Mariano F, DeMartino A, Montrucchio G, Camussi G, LaGreca G: Removal of platelet-activating factor in experimental continuous arteriovenous hemofiltration. Crit Care Med 1995;23:99–107.
22.
Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J: Haemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intens Care Med 1997;23:878–884.
23.
Cole L, Bellomo R, Journois D, Davenport P, Tipping P, Ronco C: A phase II randomized controlled trial of continuous hemofiltration in sepsis. Submitted.
24.
Heering P, Morgera S, Schmitz FJ, Willers R, Schultheiss HP, Strauer BE, Grabensee B: Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intens Care Med 1997;23:288–296.
25.
Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM: Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747–1754.
26.
Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, Dan M, Irone M, LaGreca G, Ingaggiato P, Maggiore U, De Nitti C, Wratten ML, Tetta C: A pilot study on couplet plasma filtration with adsorption in septic shock. Crit Care Med, in press.
27.
Grootendorst AF, van Bommel EFH, van der Hoven B, van Leengoed LAM, van Osta ALM: High volume hemofiltration improves hemodynamics of endotoxin-induced shock in the pig. J Crit Care 1992;7:67–75.
28.
Grootendorst AF, van Bommel EFH, van der Hoven B, van Leengoed LAM, van Osta ALM: High volume hemofiltration improves right ventricular function of endotoxin-induced shock in the pig. Intens Care Med 1992;18:235–240.
29.
Grootendorst AF, van Bommel EF, van Leengoed LA, van Zanten AR, Huipen HJ, Groeneveld AB: Infusion of ultrafiltrate from endotoxemic pigs depresses myocardial performance in normal pigs. J Crit Care 1993;8:161–169.
30.
Grootendorst AF, van Bommel EFH, van Leengoed LAM, Naburus M, Bouman CSC, Groeneveld ABJ: High volume hemofiltration improves hemodynamics and survival of pigs exposed to gut ischemia and reperfusion. Shock 1994;2:72–78.
31.
Lee PA, Matson JR, Pryor RW, Hinshaw LB: Continuous arteriovenous hemofiltration therapy for staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1993;21:914–924.
32.
Rogiers P, Zhang H, Smail N, Auwels D, Vincent JL: Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. Crit Care Med 1999;27:1848–1855.
33.
Yekebas EF, Eisenberger CF, Ohnesorge H, Saalmueller A, Elsner HA, Engelhardt M, Gillesen A, Mains J, The M, Strate T, Busch C, Knoefel WT, Bloechle C, Izbicki JR: Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis. Crit Care Med 2001;29:1423–1430.
34.
Nagashima M, Shin’oka T, Nollert G, Shum-Tim D, Rader CM, Mayer JE Jr: High-volume continuous hemofiltration during cardiopulmonary bypass attenuates pulmonary dysfunction in neonatal lambs after deep hypothermic circulatory arrest. Circulation 1998;98(suppl 19):II378–384.
35.
Bellomo R, Kellum JA, Gandhi CR, Pinsky MR: The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med 2000;161:1429–1436.
36.
Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, LaGreca G: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet 2000;356:26–30.
37.
Journois D, Israel Biet D, Pouard P, et al: High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology 1996;85:965–976.
38.
Oudemans-van Straaten HM, Bosman RJ, van der Spoe JI, Zandstra DF: Outcome of critically ill patients treated with intermittent high-volume haemofiltration: A prospective cohort analysis. Intens Care Med 1999;25:814–821.
39.
Lonnemann G, Bechstein M, Linnenweber S, Burg M, Koch KM: Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure. Kidney Int 1999;56(suppl 72):S84–87.
40.
Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P: High-volume hemofiltration in human septic shock. Intens Care Med 2001;27:978–986.
41.
Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, Hique G, Matson JR: Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000;28:3581–3587.
42.
Guth HJ, Zschiesche M, Panzig E, Rudolph PE, Jager B, Kraatz G: Which organic acids does hemofiltrate contain in the presence of acute renal failure? Int J Artif Organs 1999;22:805–810.
43.
Cole L, Bellomo R, Baldwin I, Hayhoe M, Ronco C: The impact of lactate-buffered high-volume hemofiltration on acid-base balance. Submitted.
44.
Barenbrock M, Hausberg M, Matzkies F, de la Motte S, Schaefer RM: Effects of bicarbonate- and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients. Kidney Int 2000;58:1751–1757.
45.
Davenport A, Will EJ, Davison AM: Hyperlactatemia and metabolic acidosis during hemofiltration using lactate-buffered fluids. Nephron 1991;59:461–465.
46.
Sims CA, Wattanasirichaigoon S, Menconi MJ, Ajami AM, Fink MP: Ringer’s ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. Crit Care Med 2001;29:1513–1518.
47.
Soriano FG, Liaudet L, Marton A, Hasko G, Lorigados BC, Deitch EA, Szabo C: Inosine improves gut permeability and vascular reactivity in endotoxic shock. Crit Care Med 2001;29:703–708.
48.
Bellomo R, Baldwin I, Cole L, Ronco C: Preliminary experience with high-volume hemofiltration in human septic shock. Kidney Int 1998;53(suppl 66):182–185.
49.
Lee PA, Weger G, Pryor RW, Matson JR: Effects of filter pore size on efficacy of continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1998;26:730–737.
50.
Kline JA, Gordon BE, Williams C, Blumenthal S, Watts JA, Diaz-Buxo J: Large-pore hemodialysis in acute endotoxin shock. Crit Care Med 1999;27:588–596.
51.
Morgera S, Buder W, Lehmann C, Ziemer S, Haase M, Rocktaeschel J, Beck W, Buck R, Goehl H, Kox WJ, Neumayer HH: High cut off membrane haemofiltration in septic patients with multiorgan failure: A preliminary report (abstract). Blood Purif 2000;18:61.
52.
Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, Presneill JJ: Plasmafiltration in Sepsis Study Group: Continuous plasma filtration in sepsis syndrome. Crit Care Med 1999;27:2096–2104.
53.
Tetta C, Cavaillon JM, Schulze M, Ronco C, Ghezzi PM, Camussi G, Serra AM, Curti F, Lonnemann G: Removal of cytokines and activated complement components in an experimental model of continuous plasma filtration coupled with sorbent adsorption. Nephrol Dial Transplant 1998;13:1458–1464.
54.
Tetta C, Gianotti L, Cavaillon JM, Wratten ML, Fini M, Braga M, Bisagni P, Giavaresi G, Bolzani R, Giardino R: Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock. Crit Care Med 2000;28:1526–1533.
55.
Brendolan A, Bellomo R, Tetta C, Piccinni P, Digito A, Wratten ML, Dan M, Irone M, LaGreca G, Ingaggiato P, Ronco C: Coupled plasma filtration adsorption in the treatment of septic shock. Contrib Nephrol 2001;132:383–390.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.